TypbarTCV

Typbar TCV is a typhoid conjugate vaccine developed by Bharat Biotech International Limited (BBIL) for protection against typhoid fever caused by Salmonella Typhi. The vaccine uses the Vi polysaccharide of S. Typhi conjugated to CRM197, a nontoxic variant of the diphtheria toxin, which converts the Vi antigen into a T-cell–dependent form to induce a stronger and longer-lasting immune response in infants and young children.

Indications and administration: Typbar TCV is indicated for active immunization against typhoid fever in individuals aged 6 months and older. It is given by intramuscular injection, typically as a single 0.5 mL dose. In many settings, a single-dose schedule provides protection, though local guidelines may vary and booster recommendations can differ by country or program.

Efficacy and safety: Clinical studies have demonstrated strong immunogenicity and protective efficacy in vaccinated children and adults. The vaccine generally has a favorable safety profile, with common adverse events including injection-site pain or swelling and mild fever. Serious adverse events are rare.

Regulatory status and use: Typbar TCV has been prequalified by the World Health Organization, enabling procurement by UN agencies and inclusion in national immunization programs in typhoid-endemic regions. It has been adopted in multiple countries across Asia and Africa as part of typhoid control strategies, often integrated into routine childhood immunizations or outbreak response efforts.

Overall, Typbar TCV represents a key tool in reducing typhoid incidence, including disease caused by antibiotic-resistant Salmonella Typhi strains, through broader protection in early childhood.